SEATTLE, June 1, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (“CTI”) (Nasdaq and MTA: CTIC) will host an investor and analyst meeting to discuss unmet medical needs and targeted agents in myelofibrosis and high-risk myelodysplastic syndrome/acute myeloid leukemia, including data from pacritinib, the product candidate that CTI has agreed to acquire, and CTI’s product candidate tosedostat. The event will take place on Sunday, June 3, 2012 in Chicago, Illinois. The American Society of Clinical Oncology Annual Meeting is being held in Chicago from June 1-5, 2012.
Speakers at the event will include: Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer Center, Houston, Texas; Elihu Estey, M.D., Seattle Cancer Care Alliance, Seattle, Wash., Rami Komrokji, M.D., Moffitt Cancer Center, Tampa, Fla.; and David Steensma, M.D., F.A.C.P., Dana-Farber Cancer Institute, Boston, Mass.
The presentations will begin at 7 a.m. CDT /8 a.m. EDT /5 a.m. PDT /2 p.m. CET and conclude at approximately 8 a.m. CDT /9 a.m. EDT /6 a.m. PDT /3 p.m. CET. The presentations will be webcast live with slides and archived at www.celltherapeutics.com.
About Pacritinib
Pacritinib is an oral, once a day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FMS-like tyrosine kinase 3 (FLT3). Mutations in these kinases have been shown to be directly related to the development of a variety of blood related cancers including MPD, leukemia and lymphoma. Pacritinib has demonstrated encouraging results in phase 1 and 2 studies for patients with myelofibrosis and a phase 3 study is planned in this disease.
FLT3 is a commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome suggesting a possible future role for treatment of AML.
About Tosedostat
Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials. CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors
Medical Information Contact:
T: 800.715.0944
E: info@askarm.com
SOURCE Cell Therapeutics, Inc.
